Neurocrine Biosciences | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
ALKERMES USD 146.5M 168.54M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amgen USD 5.97B 781M 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Cytokinetics -160545000 81.19M 2024-09
Dynavax Technologies USD 58.62M 8.92M 2024-12
Exelixis USD 546.79M 24.58M 2025-01
Gilead Sciences USD 5.99B 17M 2024-12
Halozyme Therapeutics USD 255.95M 15.3M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Intra Cellular Therapies USD 178.82M 18.75M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Pfizer USD 12.11B 718M 2024-12
Prothena -59001000 66.45M 2024-09
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Repligen USD 77.49M 220K 2024-09
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Teva Pharmaceutical Industries USD 2.12B 85M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Neurocrine Biosciences Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.